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Abstract
Background: In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase
inhibitors (TKIs) of EGFR, gefinitib and erlotinib, have been used with variable benefit.
Methods: We have analyzed outcome data of a population of NSCLC patients that received these
TKIs to determine the benefit derived and to define the clinical and molecular parameters that
correlate with response. Tumor tissue from a subgroup of these patients was analyzed by
immunohistochemistry to measure the expression level of EGFR and four activated
(phosphorylated) members of the pathway, pEGFR, pERK, pAKT, and pSTAT3.
Results: Erlotinib was slightly superior to gefitinib in all measures of response, although the
differences were not statistically significant. The most robust clinical predictors of time to
progression (TTP) were best response and rash (p < 0.0001). A higher level of pEGFR was
associated with longer TTP, while the total EGFR level was not associated with response. Higher
levels of pAKT and pSTAT3 were also associated with longer TTP. In contrast, a higher level of
pERK1/2 was associated with shorter TTP.
Conclusion: These observations suggest the hypothesis that tumor cells that have activated EGFR
pathways, presumably being utilized for survival, are clinically relevant targets for pathway
inhibition. An accurate molecular predictive model of TKI response should include activated
members of the EGFR pathway. TKIs may be best reserved for tumors expressing pEGFR and
pAKT or pSTAT, and little pERK. In the absence of molecular predictors of response, the
appearance of a rash and a positive first scan are good clinical indicators of response.
Background
Current chemotherapy combinations for advanced non-
small cell lung cancer (NSCLC) have reached a plateau in
overall response rate and are never curative. Response
rates for first line and second line treatments are 35% and
8%, respectively, and time to progression averages four to
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six months [1-3]. New therapeutic agents and strategies to
maximize the efficacy of current treatments are clearly
needed.
In addition to classic cytotoxic agents, approved systemic
therapies to treat NSCLC include inhibitors of the epider-
mal growth factor receptor (EGFR) pathway. The EGFR
pathway is a principal transducer of growth and survival
signals in lung cancer cells and therefore a logical target
for therapy. Gefitinib and erlotinib are reversible inhibi-
tors of the kinase domain of EGFR that compete with ATP
for binding to the catalytic pocket. These small molecules
inhibit EGFR autophosphorylation and, thus, they inhibit
receptor dimerization, and the downstream signaling that
would have otherwise stimulated proliferation (through
the activation of Erk) and anti-apoptotic mechanisms
(through activation of Akt and Stat).
TKIs were developed after accumulating evidence indi-
cated that a large proportion of NSCLC over-expresses the
EGF receptor and is likely to be dependent on this path-
way for the malignant phenotype [4]. However, TKIs in
NSCLC therapy have not produced the gains in survival
and time to progression that were anticipated when used
alone or in combination with traditional cytotoxic agents
[2,3,5]. Given this limitation, one way to increase the
effectiveness of these agents is to rationally select patients
based on tumor markers that predict response.
The identification of molecular predictors of response to
anti-EGFR agents has been difficult. Unlike trastuzumab,
whose clinical activity can be predicted by the evidence of
over-expression of its target, the ErbB2 receptor, either by
fluorescence in situ hybridization (FISH) or immunohis-
tochemistry (IHC) [6], single markers have not produced
accurate predictive models of response for anti-EGFR
agents such as gefitinib and erlotinib. Early results on the
relationship between EGFR protein overexpression or egfr
gene amplification and response were contradictory and
recent large studies indicate that there is no correlation
between high EGFR expression by IHC or amplification
by FISH and better response to TKIs [5,7-9]. Specific muta-
tions in the egfr gene have correlated with the dramatic
responses that are sometimes seen in a small percentage of
patients treated with these agents. However, these results
are confounded by the prognostic value of the mutations,
since it has been noted that these patients have a better
prognosis, regardless of treatment used, than patients
whose tumors do not bear egfr mutations [10]. Moreover,
the mutations do not identify the large number of patients
that achieve more modest responses.
We evaluated data from our lung cancer patients to com-
pare the benefits derived from erlotinib and gefitinib and
to identify the clinical parameters that correlated with
response. We subsequently analyzed tumor tissue from a
subgroup of these patients for a pilot study to evaluate the
utility of a combination of markers, downstream from the
inactivated EGFR receptor, to predict response to TKIs and
correlate outcomes. We based our design on the hypothe-
sis that an accurate predictive model may need several
markers, and that markers closer to the malignant pheno-
type (activated, phosphorylated proteins) may be better
predictors than DNA/RNA markers or inactive (unphos-
phorylated) protein markers. In order to determine which
tumor will be susceptible to anti-EGFR therapy, one may
need to assess the level of phosphorylated EGFR as well as
the level of phosphorylated downstream mediators, Akt,
Erk1/2 and Stat3, the cytosolic end points to the three
branches of the EGFR signaling pathway. Moreover, clini-
cal data have identified these markers as relevant to the
natural history of lung cancer [11-15].
Methods
Patient Data
At the Maine Center for Cancer Medicine, clinical data
were compiled for 160 NSCLC patients that had received
either gefitinib or erlotinib between 1996 and 2002 and
organized into a database constructed in FileMaker Pro 8.
Recorded variables included age, sex, smoking history,
ECOG performance status score, date of diagnosis, stage at
diagnosis, treatments, and toxicities. Outcome data
included best response, time to progression, survival since
start of TKI treatment, and overall survival. Best response
to the new therapeutic agent was documented in the first
computed tomography (CT) scans done 3-4 months after
the start of TKI therapy. Time to progression was defined
as the time interval from the initiation of TKI therapy to
the time of disease progression as evidenced by CT scan or
by a decline in performance status. Survival since TKI
treatment was defined as the time interval from initiation
of TKI therapy to death.
Paraffin-embedded tumor samples were obtained from a
subgroup of patients (n = 32) that had received gefitinib
or erlotinib and had adequate histological material.
Twenty three of these were primary lung tumor resection
samples, six were lymph node samples, and three were
samples from other biopsy sites. All samples had been
fixed in 10% buffered formalin. Clinical data were kept
unavailable during the laboratory analysis until all data
were evaluated. This study was approved by the Maine
Medical Center Institutional Review Board.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumor samples were
cut in 4 m-thick sections. Consecutive sections were then
treated with primary antibodies purchased from Cell Sig-
naling Technologies (Beverly, MA, USA) to visualize phos-
pho-EGFR (Tyr1173) (53A5 rabbit mAb), phospho-AktBMC Cancer 2009, 9:333 http://www.biomedcentral.com/1471-2407/9/333
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(Ser473) (736E11 rabbit mAb), phospho-Stat3 (Tyr705)
(D3A7 rabbit mAb) and phospho-Erk1/2 (Thr202/
Tyr204) (20G11 rabbit mAb), according to the manufac-
turer's instructions. Primary antibodies were visualized
with biotinylated secondary antibodies, streptavidin/HRP
enzyme complex and DAB chromogen. The slides were
counterstained with hematoxylin. Total EGFR levels were
obtained from sections sent to NorDx Laboratories and
stained on a Ventana BenchMark XT automated stainer
using anti-EGFR mouse monoclonal antibody 3C6 and
Basic DAB Detection kit (Ventana Medical Systems, Tuc-
son, AZ, USA). Protocols were pre-tested using positive
and negative control cell pellets for each anti-phospho
protein antibody, available through Cell Signaling Tech-
nologies. Sections were scanned at low magnification and
portions containing tumor tissue were delineated by the
study pathologist (PA). Specimens were evaluated by light
microscopy by two independent observers and scored
based on a semiquantitative approach of percentage of
positive tumor cells (0-100%), multiplied by staining
intensity (0 = negative, 1 = weak, 2 = moderate, 3 =
strong). In cases in which there were tumor cell popula-
tions within one sample with clear distinction in staining
intensities, each region's intensity was multiplied by the
appropriate percentage and added to produce the sample
score. The final percentage of cells staining and score for
each slide was calculated as the average between the per-
centage and scores of the two observers. For example, a
sample that was scored by one observer as having 100%
of cells staining, with 50% of them staining at intensity 1
and 50% at intensity 2, and was scored by the second
observer as having 80% of cells staining, with 70% of
them staining at intensity 1 and 10% at intensity 2, would
receive a score of 150 [(50 × 1) + (50 × 2)] from observer
one, and a score of 90 [(70 × 1) + (10 × 2)] from observer
two. Accordingly, in this sample, the final percentage of
cells staining would be 90% (mean between 100% and
80%), and the final score would be 120 (mean between
150 and 90). In this manner, a total score range of 0-300
was generated for each sample, where 0 was classified as
no expression, 1-10 was classified as low expression, 11-
100 was classified as moderate and 101-200 was classified
as moderate-high expression level, and scores over 200
were classified as high expression level. The distribution
of staining (membranous, cytoplasmic, or nuclear) was
recorded. Positive expression of pERK1/2 in stromal
fibroblasts and endothelial cells of tumor tissue was used
as an internal standard of tissue quality and antigen pres-
ervation.
Statistical Analysis
Univariate analysis between time to progression and sur-
vival according to best response, and appearance of rash
were conducted using the Kaplan-Meier method. For the
patients with tissue sample (n = 32), the associations
between time to progression and survival according to
level of expression of four phospho-proteins, and total
EGFR were investigated using Rapid Insight Analytics sta-
tistics program software, and box plots analyses with Excel
and XLSTAT program software.
Results
Response to tyrosine kinase inhibitors
Between 1996 and 2002, 160 patients with NSCLC
received a tyrosine kinase inhibitor during treatment at
Table 1: Patient characteristics
Gefitinib Erlotinib
No % No %
TOTAL 115 45
Gender
Female 55 48 30 67
Male 60 52 15 33
Age
Avg. age 66.53 66.76
Range 45-86 35-82
Smoking history
Smokers 109 95 39 87
Non-smokers 5 1 4 9
Unknown 1 1 2 4
Avg. pack-years 43.6 42.2
Histology
Adenocarcinoma 54 47 15 33
Squamous 27 23 9 20
Bronchioalveolar 8 6 2 4
Large cell 6 5 0 0
Mixed 2 2 0 0
NSC not further specified 17 15 20 44
Avg. ECOG 1.37 1.37
Avg. previous lines of chemo 1.26 1.13BMC Cancer 2009, 9:333 http://www.biomedcentral.com/1471-2407/9/333
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the Maine Center for Cancer Medicine. One hundred and
fifteen (115) patients received gefinitib and forty five (45)
received erlotinib. We analyzed the baseline characteris-
tics of these two populations and found them to be nearly
equivalent in regards to age, smoking history, ECOG per-
formance, stage, and number of previous line of chemo-
therapy. The population of erlotinib users had a higher
proportion of females as compared to the population of
gefitinib users (Table 1).
As assessed by CT scans within 3-4 months after the initi-
ation of therapy or by clinical examination when declin-
ing performance status prevented scanning, most patients
in the gefitinib group had progressive disease (65%), but
a quarter had stable disease (26%) and a small minority
had a response (3% CR and 3% PR). In contrast almost
half the patients in the erlotinib group experienced stable
disease (47%) and 10% had a response (5% CR and 5%
PR), while 41% showed progressive disease. The longest
time to progression was 35 months for erlotinib and 72
months for gefitinib. The patient that experienced no pro-
gression for over 6 years was a Caucasian female with a
100 pk/year smoking history.
The most common side-effects for both groups were rash,
followed by diarrhea, nausea/vomiting and fatigue (Table
2). In the gefitinib group, four patients had significant
anorexia and three had clinically evident interstitial lung
disease, with swelling/scarring of alveoli and interstitium.
Twenty percent of patients in the gefitinib and 17% in the
erlotinib group discontinued therapy due to the side-
effects. Median time to progression and survival since TKI
treatment were, respectively, 2.8 and 7.6 months in the
erlotinib group, and 2.4 and 5.0 months in the gefitinib
group, but these differences were not statistically signifi-
cant (Figures 1a-b).
Clinical predictors of response
Rash was the most common side effect for both groups of
patients, and in agreement with previous studies, we
found that the development of rash correlated with clini-
cal benefit [16]. The median TTP among patients that
experienced a rash was 3.8 months as compared to 1.9
months among the patients that did not experienced a
rash. Median survival after the start of therapy was 8.9
months among those with a rash and 3.8 months among
those without a rash. Kaplan-Meier analyses indicated
that these differences were statistically significant (P value
of < 0.0001, Figure 2a-b). Moreover, these differences per-
sisted when the erlotinib and gefitinib data sets were ana-
lyzed separately (data not shown).
We also investigated outcome in patients that showed
progressive disease as compared to those that achieved
disease control (defined as CR+PR+SD). Among patients
that experienced disease control, the median TTP and the
median survival since TKI were 5.1 and 12.2 months,
respectively. On the other hand, among the patients that
experienced progressive disease, the median TTP and sur-
vival since TKI were only 1.7 and 2.9 months, respectively.
Kaplan-Meier analyses confirmed that these differences
were statistically significant (P value of < 0.0001 Figures
3a-b).
Immunohistochemistry
For the 32 patients that had sufficient tissue available, we
used immunohistochemistry (IHC) to measure the levels
of phosphorylated EGFR (pEGFR), phosphorylated Akt
(pAkt), phosphorylated Stat3 (pStat3) and phosphor-
ylated Erk1/2 (pErk1/2) proteins. We also measured the
level of total EGFR expression for comparison (See Addi-
tional file 1). There were a wide range of protein expres-
sion levels. As expected, both total and phosphorylated
EGFR, was found to be membrane-associated. Phosphor-
ylated Stat 3 localized to nuclei and pErk1/2 and pAkt
localized to nuclei and cytoplasm. In general, the expres-
sion level of the phosphorylated proteins was significantly
less than that of total EGFR and the signal from phospho-
rylated antigens was more prominent in tumor cells
located toward the periphery of the tissue. Four tumor
samples were selected to represent the range of expression
observed (Figure 4). Total EGFR was the antigen with the
Table 2: Side effects
Gefitinib Erlotinib
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
No % No % No % No %
Skin rash 40 35 6 5 24 53 2 4
Diarrhea 35 30 8 7 15 33 2 4
Nausea/Vomiting 8 7 7 16 1 2
Fatigue 5 4 2 2 3 7 2 4
Anorexia 4 3 1 1
Instertitial Lung Disease 3 3BMC Cancer 2009, 9:333 http://www.biomedcentral.com/1471-2407/9/333
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Gefinitib vs. erlotinib Figure 1
Gefinitib vs. erlotinib. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI therapy (b) in 
months among gefitinib users (solid line) and erlotinib users (dashed line).
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Rash vs. no rash Figure 2
Rash vs. no rash. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI therapy (b) in months 
among patients that developed a skin rash (solid line) and patients that did not developed rash (dashed line).
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Disease control vs. progressive disease Figure 3
Disease control vs. progressive disease. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI 
therapy (b) in months among patients that had a response or stable disease (solid line) and patients that had progressive dis-
ease (dashed line).
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highest expression levels and it was detected in all tumor
samples. The second most widely expressed antigen was
pErk1/2 followed by pStat3. pEGFR and pAkt were weakly
expressed in most samples.
Association between phospho-protein level and response 
to gefitinib
We calculated the mean and median TTP as a function of
the expression levels (none, low, moderate, moderate
high and high) of our five protein markers, total EGFR,
pEGFR, pAkt, pStat3 and pErk1/2. We found no discerna-
ble association between TTP and the level of total EGFR.
On the other hand, we found a positive association
between TTP and the level of pEGFR: in general, the
higher the level of this protein, the longer the TTP.
Patients with no discernable pEGFR signal had a median
TTP of 2.0 months while patients with moderate pEGFR
levels had a mean TTP of 3.5 months (Figures 5a-b). pAkt
and, to a lesser extent, pStat3 were also slightly positively
associated with longer TTP (Figures 5c-d). In contrast,
phosphorylated Erk1/2 displayed a negative association
with TTP: the higher the level of this protein, the shorter
the TTP. Patients with little or no detectable levels of
pErk1/2 had a median TTP of 4.2 months while patients
with high levels of pErk1/2 had a mean TTP of 0.6 months
(Figure 5e). When the levels of the four phospho-proteins
were compared amongst each other, we found a strong
positive correlation between the level of pEGFR and the
level of pStat3 that reached statistical significance (p <
0.0001).
Discussion
The identification of patients that are likely to benefit
from EGFR TKI therapy is a priority for patients with
advanced non-small cell lung cancer. A recent study
showed that TKI therapy-induced rash strongly correlated
with better disease control and progression free survival,
and concluded that the development of rash should be
viewed as an indication of likelihood of clinical benefit
[16]. In this study, we also found that the appearance of
rash correlated with longer TTP and survival with TKI
treatment. In addition, we found that patients who
achieved some degree of disease control at the first
response evaluation had a significantly better outcome
than patients who experienced disease progression.
Although early clinical indicators of response are useful,
the identification of pre-treatment predictors of benefit
would be even more desirable. We hypothesized that
tumors that are actively using the EGFR pathway for sur-
vival and growth would be most susceptible to TKI ther-
apy-mediated inhibition. We also hypothesized that the
activation status of the EGFR pathway could be assessed
by evaluating the phosphorylation level of key members
of the pathway, rather than total protein levels. Accord-
ingly, we determined the expression levels of the activated
receptor (pEGFR), and the activated cytosolic end points
to the three branches of the EGFR pathway (pAkt, pStat3
and pErk1/2) in pre-treatment samples of tumor tissue
from patients undergoing TKI therapy and response
assessment.
In general, the expression level of the phosphorylated pro-
teins was significantly less than that of total EGFR. This
reflects the fact that the phospho-proteins are more labile
and more difficult to detect than total protein levels [17].
In agreement with this, we found that the signal from
phosphorylated antigens was more prominent in tumor
cells located toward the periphery of the tissue blocks as
opposed to cells in more internal regions. We presume
that the time delay that occurs from the immersion of the
block in fixative to its complete permeation results in the
observed pattern of expression. Interestingly, when we
compared the levels of the four phospho-proteins
amongst each other, we found a significant correlation
between the level of pEGFR and pStat3, in general agree-
ment with the notion that the activation of the receptor
gets transduced most directly to pStat3 in the signaling
pathway.
Analysis of the association between outcome and phos-
pho-protein expression suggested that the pattern of
expression may be useful as a predictor of clinical benefit
from TKI therapy. However, the small number of samples
precluded obtaining statistically significant results. Higher
levels of pEGFR, pAkt, and pStat3 were associated with
longer TTP, while higher levels of pErk1/2 were associated
with shorter TTP. These results make biologic sense given
the presumed position of these proteins in the pathway.
pAkt and pStat are thought to mediate cell survival, and it
Immunohistochemistry Figure 4
Immunohistochemistry. Immunohistochemical analyses 
of the five protein targets in four representative tumor sam-
ples. EGFR (total and phosphorylated) localized to the mem-
brane. pStat 3 localized to nuclei and pErk1/2 and pAkt 
localized to both nuclei and cytoplasm.BMC Cancer 2009, 9:333 http://www.biomedcentral.com/1471-2407/9/333
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Time to progression by expression level Figure 5
Time to progression by expression level. Box Plot Analyses of the association between lengths of time to progression 
according to the expression levels of a) total EGFR, b) phosphorylated EGFR, c) phosphorylated Akt, d) phosphorylated Stat3 
and e) phosphorylated Erk1/2. Time to progression is expressed in months. Expression levels are expressed in four categories 
zero, low, moderate, moderate-high, and high, where zero represents samples with no detected signal, low for scores between 
1 and 10, moderate for scores between 11 and 100, moderate-high for scores between 101 and 200 and high for scores 
between 201 and 300. Each box represents the TTP values between the 1st and the 3rd quartile. The line across each box rep-
resents the median TTP. The dash at the end of the lines represents the maximum and minimum TTP. The crosses represent 
the mean TTP for each category.
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is possible that detecting these proteins indicates that a
tumor is using the pathway for survival and that inhibi-
tion of the pathway provokes widespread apoptosis. On
the other hand, pErk, mediates cell proliferation and is
downstream of ras, a gene that is often mutated in these
tumors. High levels of pErk may reflect activation of ras
rather than EGFR, a condition where EGFR TKI would be
ineffective.
Conclusion
In our experience, erlotinib was found slightly superior to
gefitinib in objective response rate and disease control
rate, but in terms of time to progression and survival after
treatment, the two agents were statistically comparable.
In the absence of molecular predictors of response, the
appearance of a rash and evidence of disease control at
first follow-up exams are good indicators of response to
TKIs. In combination, pEGFR, pAKT, pStat3 and pErk1/2
are promising predictive markers of response to EGFR TKI
and deserve further analysis.
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